{"product_id":"schizophrenia-current-science-and-clinical-practice-hardback-9780470710548","title":"Schizophrenia; Current science and clinical practice (Hardback) 9780470710548","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eSchizophrenia\u003c\/font\u003e\u003cbr\u003e\r\n\u003cfont size=\"5\"\u003eCurrent science and clinical practice\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\u003cp\u003e\u003cfont size=\"4\"\u003eWolfgang Gaebel (Edited by), W Gaebel (Author)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9780470710548, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 13 April 2011\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e272 pages\u003cbr\u003e25.2 x 17.6 x 2 cm, 0.612 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cem\u003e\u003cfont size=\"3\"\u003e\u003cp\u003e“Professor Gaebel and contributing authors are to be congratulated for this outstanding text.”  (\u003ci\u003eJournal of Clinical Psychiatry\u003c\/i\u003e, 6 June 2012)\u003c\/p\u003e \u003cp\u003e\"Nonetheless, Schizophrenia: Current Science and Clinical Practice will be an asset to those who are seeking a current and sophisticated synthesis of the field, combined with stimulating discussions of some pivotal controversies in both research and treatment. Gaebel has assembled a distinguished group of contributors who are more than up to the task of grappling with the challenge of discerning the implications of cutting-edge research for clinical intervention.\" (PsycCRITIQUES, 11 January 2012)\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e \u003cp\u003e\"I am not in a position to comment on most chapters, as I am not an expert in those fields, but all I can say is that I learnt a lot and that the book provided me with a good overview on different aspects of what we commonly call schizophrenia.\" (Acta Psychiatr Scandinavica, 2012)\u003c\/p\u003e \u003cp\u003e\"The first chapter is an excellent and factual review of the diagnosis and classification systems that highlights the major validity issues. . .This new book is useful and current.\" (Doody's, 30 September 2011)\u003c\/p\u003e \u003cp\u003e\"The book will be of interest to psychiatrists, psychologists, neuropharmacologists, researchers in psychiatry and psychopharmacology, and clinical and behavioral neuroscientists.\" (Book News, 1 August 2011)\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e\u003c\/font\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003eThe first book in a new series from the World Psychiatric Association, \u003ci\u003eSchizophrenia: current science and clinical practice\u003c\/i\u003e presents recent information on the diagnosis, neurobiological foundations, and management of schizophrenia. It evaluates the findings obtained with modern techniques like magnetic resonance imaging, genetics and network analyses.  The book reviews the importance of neurocognitive functioning in schizophrenia and its predictive value for functional capacity.  It covers the key areas of early recognition, prevention, rehabilitation and stigma.  There is also a critical discussion of diagnostic classification and the revision of the two major international systems.   \u003cp\u003eWritten by experts in the field who have a track record of being engaging authors, this book provides a rapid overview of the current state of the art in schizophrenia research and clinical management.  It will be invaluable to all psychiatrists, psychologists, neuropharmacologists, researchers in psychiatry and psychopharmacology in academia and in industry, and clinical and behavioural neuroscientists.\u003c\/p\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eList of Contributors.  \u003cp\u003ePreface.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Diagnosis and revision of the classification systems\u003c\/b\u003e (\u003ci\u003eAssen Jablensky\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eOrigin and evolution of the concept of schizophrenia.\u003c\/p\u003e \u003cp\u003eKraepelin's 'clinical forms'.\u003c\/p\u003e \u003cp\u003eBleuler's 'group of schizophrenias'.\u003c\/p\u003e \u003cp\u003eLeonhard's 'endogenous psychoses'.\u003c\/p\u003e \u003cp\u003eClassification of psychoses in French psychiatry.\u003c\/p\u003e \u003cp\u003eOther post-Kraepelinian and post-Bleulerian subtypes and dichotomies.\u003c\/p\u003e \u003cp\u003eThe schizophrenia spectrum concept.\u003c\/p\u003e \u003cp\u003eStatistically derived clusters and symptom dimensions.\u003c\/p\u003e \u003cp\u003eSchizophrenia in ICD-10 and DSM-IV.\u003c\/p\u003e \u003cp\u003eOrigins of the two classifications.\u003c\/p\u003e \u003cp\u003eBoth DSM-IV and ICD-10 are descendants of the Kraepelinian nosology.\u003c\/p\u003e \u003cp\u003eCriteria for assessing the diagnostic classification of schizophrenia.\u003c\/p\u003e \u003cp\u003ePositive impact and unintended adverse effects.\u003c\/p\u003e \u003cp\u003eClinical relevance and cognitive ease of use.\u003c\/p\u003e \u003cp\u003eUtility in research.\u003c\/p\u003e \u003cp\u003eReliability.\u003c\/p\u003e \u003cp\u003eConcepts of validity.\u003c\/p\u003e \u003cp\u003ePredictive validity: course and outcome.\u003c\/p\u003e \u003cp\u003eCriterion validity: genetics.\u003c\/p\u003e \u003cp\u003eAspects of culture.\u003c\/p\u003e \u003cp\u003eReducing stigma.\u003c\/p\u003e \u003cp\u003eRevision of the classifications: prospects for schizophrenia.\u003c\/p\u003e \u003cp\u003eOne classification or many?\u003c\/p\u003e \u003cp\u003eCritical issues in the revision process.\u003c\/p\u003e \u003cp\u003eDisease or a broad syndrome?\u003c\/p\u003e \u003cp\u003e'Deconstructing' schizophrenia: categories or dimensions?\u003c\/p\u003e \u003cp\u003eEndophenotypes.\u003c\/p\u003e \u003cp\u003eThe concept of utility.\u003c\/p\u003e \u003cp\u003eConclusion.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Pathophysiology of schizophrenia\u003c\/b\u003e (\u003ci\u003ePeter Falkai, Andrea Schmitt and Tyrone D. Cannon\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eMajor findings and related pathophysiological hypotheses.\u003c\/p\u003e \u003cp\u003eSymptom domains and neurotransmitter hypotheses.\u003c\/p\u003e \u003cp\u003eFrom domains to disturbed neuronal networks.\u003c\/p\u003e \u003cp\u003eFrom networks to the cellular level.\u003c\/p\u003e \u003cp\u003eHypothesis of disturbed synaptogenesis and neurogenesis.\u003c\/p\u003e \u003cp\u003eEffects of antipsychotics.\u003c\/p\u003e \u003cp\u003eSummary and conclusions.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Neurocognition, social cognition and functional outcome in schizophrenia\u003c\/b\u003e (\u003ci\u003eWilliam P. Horan, Philippe-Olivier Harvey, Robert S. Kern and Michael F. Green\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eNeurocognition in schizophrenia.\u003c\/p\u003e \u003cp\u003eDomains, measurement and magnitude of impairment.\u003c\/p\u003e \u003cp\u003eNeurocognition as a core deficit of schizophrenia.\u003c\/p\u003e \u003cp\u003eAssociations with functional outcome.\u003c\/p\u003e \u003cp\u003eThe NIMH-MATRICS initiative and current research directions.\u003c\/p\u003e \u003cp\u003eSocial cognition.\u003c\/p\u003e \u003cp\u003eDomains, measurement and magnitude of impairment.\u003c\/p\u003e \u003cp\u003eSocial cognition as a core feature of schizophrenia.\u003c\/p\u003e \u003cp\u003eAssociation with functional outcome.\u003c\/p\u003e \u003cp\u003eCurrent research directions.\u003c\/p\u003e \u003cp\u003eRelationships among neurocognition, social cognition and functional outcome.\u003c\/p\u003e \u003cp\u003eDistinctiveness of neurocognition and social cognition.\u003c\/p\u003e \u003cp\u003eSocial cognition as a mediator.\u003c\/p\u003e \u003cp\u003eFuture directions.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 The genetics of schizophrenia\u003c\/b\u003e (\u003ci\u003eJames T.R. Walters, Michael O'Donovan and Michael J. Owen\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eGenetic epidemiology of schizophrenia.\u003c\/p\u003e \u003cp\u003eFamily, twin and adoption studies of schizophrenia.\u003c\/p\u003e \u003cp\u003eGenetic epidemiology – informing diagnosis?\u003c\/p\u003e \u003cp\u003eMolecular genetics of schizophrenia.\u003c\/p\u003e \u003cp\u003eLinkage.\u003c\/p\u003e \u003cp\u003ePositional candidate studies.\u003c\/p\u003e \u003cp\u003eFunctional candidate studies.\u003c\/p\u003e \u003cp\u003eChromosomal abnormalities.\u003c\/p\u003e \u003cp\u003eGenome wide association studies.\u003c\/p\u003e \u003cp\u003eGWAS in schizophrenia.\u003c\/p\u003e \u003cp\u003eCopy number variation.\u003c\/p\u003e \u003cp\u003eThe future of schizophrenia genetics.\u003c\/p\u003e \u003cp\u003eSchizophrenia genetics in the clinic?\u003c\/p\u003e \u003cp\u003eConclusions.\u003c\/p\u003e \u003cp\u003eAcknowledgements.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Early recognition and prevention of schizophrenia\u003c\/b\u003e (\u003ci\u003ePatrick D. McGorry and Sherilyn Goldstone\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eThe context for early recognition and prevention.\u003c\/p\u003e \u003cp\u003eThe prodromal stage: definition and assessment.\u003c\/p\u003e \u003cp\u003eTreatment during the prodromal stage.\u003c\/p\u003e \u003cp\u003eThe psychosis risk syndrome: a novel diagnostic entity?\u003c\/p\u003e \u003cp\u003eEthical issues.\u003c\/p\u003e \u003cp\u003eSummary and conclusions.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Pharmacological treatment\u003c\/b\u003e (\u003ci\u003eJonathan E. Sherin and Stephen R. Marder\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eCurrent state of pharmacological treatment.\u003c\/p\u003e \u003cp\u003ePhases of schizophrenia.\u003c\/p\u003e \u003cp\u003eAcute phase treatment.\u003c\/p\u003e \u003cp\u003eStabilization phase treatment.\u003c\/p\u003e \u003cp\u003eMaintenance phase treatment.\u003c\/p\u003e \u003cp\u003eTreatment resistant patients.\u003c\/p\u003e \u003cp\u003eManaging first episodes.\u003c\/p\u003e \u003cp\u003eNewer antipsychotics.\u003c\/p\u003e \u003cp\u003ePersonalising drug treatment in schizophrenia.\u003c\/p\u003e \u003cp\u003eCognition and negative symptoms as therapeutic targets.\u003c\/p\u003e \u003cp\u003eGlutamatergic targets.\u003c\/p\u003e \u003cp\u003eDopamine targets.\u003c\/p\u003e \u003cp\u003eCholinergic targets.\u003c\/p\u003e \u003cp\u003eHistamine targets.\u003c\/p\u003e \u003cp\u003eSummary.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Cognitive-behavioural interventions\u003c\/b\u003e (\u003ci\u003eSuzanne Jolley and Philippa Garety\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eThe development of cognitive behavioural approaches to schizophrenia-spectrum psychosis.\u003c\/p\u003e \u003cp\u003eCognitive behavioural models of psychosis.\u003c\/p\u003e \u003cp\u003eBiopsychosocial vulnerability.\u003c\/p\u003e \u003cp\u003eLife events and schematic beliefs.\u003c\/p\u003e \u003cp\u003eThe role of affect.\u003c\/p\u003e \u003cp\u003eThe central role of appraisal.\u003c\/p\u003e \u003cp\u003eReasoning biases.\u003c\/p\u003e \u003cp\u003eAnomalous experiences.\u003c\/p\u003e \u003cp\u003eThe role of behaviour.\u003c\/p\u003e \u003cp\u003eInsight and illness appraisals.\u003c\/p\u003e \u003cp\u003eCognitive behavioural therapy in schizophrenia.\u003c\/p\u003e \u003cp\u003ePsychotherapy in schizophrenia: more than unspecific learning?\u003c\/p\u003e \u003cp\u003eCombining psychotherapy and pharmacotherapy.\u003c\/p\u003e \u003cp\u003eEfficacy of cognitive behavioural therapy for psychosis (CBTp).\u003c\/p\u003e \u003cp\u003eFuture developments.\u003c\/p\u003e \u003cp\u003eConclusions.\u003c\/p\u003e \u003cp\u003eAcknowledgements.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Management, rehabilitation, stigma\u003c\/b\u003e (\u003ci\u003eWulf Rossler\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eManaging schizophrenia: integrative approaches.\u003c\/p\u003e \u003cp\u003eBurden for patients, families and communities.\u003c\/p\u003e \u003cp\u003eGender issues.\u003c\/p\u003e \u003cp\u003eMortality.\u003c\/p\u003e \u003cp\u003eLegal problems.\u003c\/p\u003e \u003cp\u003eHealth care settings for schizophrenia patients: which setting is optimal?\u003c\/p\u003e \u003cp\u003ePsychiatric rehabilitation.\u003c\/p\u003e \u003cp\u003eThe international classification of functioning, disability and health.\u003c\/p\u003e \u003cp\u003eTarget population.\u003c\/p\u003e \u003cp\u003eConceptual framework.\u003c\/p\u003e \u003cp\u003eCurrent approaches.\u003c\/p\u003e \u003cp\u003eIndividual-centred rehabilitation.\u003c\/p\u003e \u003cp\u003eCognitive behavioural therapy.\u003c\/p\u003e \u003cp\u003eSocial skills training.\u003c\/p\u003e \u003cp\u003eEcological approach to rehabilitation.\u003c\/p\u003e \u003cp\u003eHousing.\u003c\/p\u003e \u003cp\u003eWork.\u003c\/p\u003e \u003cp\u003eParticipation in community life with full rights.\u003c\/p\u003e \u003cp\u003eThe contribution of mental health professionals to stigma and discrimination.\u003c\/p\u003e \u003cp\u003eThe role of the psychiatrist in the management and rehabilitation of schizophrenia patients.\u003c\/p\u003e \u003cp\u003eOutlook.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIndex.\u003c\/b\u003e\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Other branches of medicine [\u003ca title=\"See our other books on Other branches of medicine\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Other%20branches%20of%20medicine%20%5BMM%5D%22\"\u003eMM\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Brand New","offer_id":52278023094552,"sku":"9780470710548","price":60.89,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9780470710548.jpg?v=1781456100","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/schizophrenia-current-science-and-clinical-practice-hardback-9780470710548","provider":"Freshly Printed Books","version":"1.0","type":"link"}